drugset / Trial / NCT06172036
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of irinotecan liposomes with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin (LV) with or without adelizumab for resectable pancreatic cancer by assessing the 12-month EFS rate
Timeline
- Start
- 2024-01-20
- Primary completion
- 2026-01-20
- Completion
- 2027-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebellizumab | Unknown | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |